Payment overview · 2025
General Payments
$218.19
13 reported records · 10 companies
Healthcare provider profile · identity verified
Christopher N. Thiessen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOOSE LAKE, MN · NPI 1306849914
Verified facts
What the public records show
CMS Open Payments records show Christopher N. Thiessen, M.D. received $218.19 in general payments during 2025 across 13 reported records.
Astellas Pharma US Inc accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.22 | 19.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.33 | 17.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.49 | 14.9% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.93 | 8.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.97 | 7.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.90 | 7.8% | 1 | 2025 |
| Cepheid | Unresolved — no canonical attribution shown | $15.25 | 7.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.99 | 6.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.22 | 6.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.89 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.19 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.22 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| GeneXpert Normalized: genexpert |
Device | Cepheid | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 192 | 47 |
| Gabapentin | Gabapentin | 177 | 39 |
| Lisinopril | Lisinopril | 163 | 45 |
| Losartan Potassium | Losartan Potassium | 161 | 42 |
| Omeprazole | Omeprazole | 159 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 28 |
| Metformin Hcl | Metformin Hcl | 91 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 87 | 22 |
| Metformin Hcl Er | Metformin Hcl | 86 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 24 |
| Sertraline Hcl | Sertraline Hcl | 78 | 20 |
| Trazodone Hcl | Trazodone Hcl | 77 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 73 | suppressed |
| Mirtazapine | Mirtazapine | 72 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 72 | 20 |
| Prednisone | Prednisone | 66 | 28 |
| Eliquis | Apixaban | 64 | 14 |
| Famotidine | Famotidine | 60 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 13 |
| Baclofen | Baclofen | 54 | 16 |
| Jardiance | Empagliflozin | 54 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 15 |
| Buspirone Hcl | Buspirone Hcl | 49 | 11 |
| Allopurinol | Allopurinol | 47 | suppressed |
| Furosemide | Furosemide | 44 | 12 |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 21 |
| Ozempic | Semaglutide | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Cephalexin | Cephalexin | 36 | 23 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 11 |
| Topiramate | Topiramate | 34 | 11 |
| Finasteride | Finasteride | 33 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Meloxicam | Meloxicam | 29 | 12 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Linzess | Linaclotide | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Levonorgestrel-Eth Estradiol | Levonorgestrel/Ethin.Estradiol | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.19 · 13 records | Astellas Pharma US Inc | AIRSUPRA, BREZTRI, Belbuca, CAPLYTA, GeneXpert, KEVEYIS, KISUNLA, Kerendia, VOQUEZNA, VRAYLAR, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error